şimedia declinului calciului serica fost semnificativ mai marela pacienţii cu disecţie centrală a gâtului şi limfadenectomie (1.94±0.59 vs. 1.68±0.56 mg/dl, p=0.033). Concluzii: Datele noastre indică o prevalenţă mare a PoSH, care este posibil să crească avand in vedere creşterea numărului de tiroidectomii efectuate.Cercetări suplimentare sunt necesare pentru a defini mai bine boala şi a stabili tratamentul şi măsurile preventive adecvate.

No abstract

Purpose Laparoscopic sleeve gastrectomy (LSG) is an effective weight loss procedure, but detrimental effects on bone health have been described. We aimed to assess the dynamics of regional and total bone mineral density (BMD) in a cohort of patients undergoing LSG and to capture gender differences in terms of evolution. Materials and Methods We conducted a retrospective study on 241 patients who underwent LSG to determine the regional and total BMD changes at 6 and 12 months after the intervention. Results One hundred ten males and 140 females (97 pre-, 43 postmenopausal) were included. Mean baseline body mass index (BMI) was 44.16 ± 6.11 kg/m2 in males and 41.60 ± 5.54 kg/m2 in females, reaching 28.62 ± 4.26 kg/m2 and 27.39 ± 4.2 kg/m2, respectively, at 12 months. BMD showed a continuous decline, with significant loss from 6 months postoperatively. There was a positive correlation between BMD and BMI decline at 12 months (r = 0.134, p < 0.05). Total BMD loss at 12 months was significantly greater in males than premenopausal females, independent of BMI variation and age. During the first 6 months, men lost significantly more bone mass than premenopausal and postmenopausal women (BMD variation was 2.62%, 0.27%, 1.58%, respectively). The second period (6–12 months) was similar in all three groups, revealing a further steady (~ 1.4%) BMD decline. Conclusions Our results are consistent with previous findings that LSG negatively impacts BMD, stressing the importance of bone health-oriented measures in postoperative care. Moreover, the impact that seems more significant in males warrants future exploration, as it might change clinical practice. Graphical abstract

No abstract

Background Quality of life of patients with rheumatoid arthritis (RA) and biological therapy can be influenced by several factors, not only the response to treatment. Amyloidosis can be one of this Objectives We investigated if the quality of life of patients with rheumatoid arthritis and various biological therapies is influenced by the existence of amyloidosis Methods We evaluated 113 RA patients (21 men and 92 women) with anti-TNF treatment between June and December 2011. We measured the patients’ health-related quality of life using the health assessment questionnaire (HAQ) and visual analog scales for global estimate of status (VAS - GS). All patients were clinically and biologically evaluated. In some patients with HAQ>1 we performed biopsy of abdominal fat to appreciate the existence of amyloidosis using special stain. Results The mean age was 53.2 years (range 21–73) and the mean disease duration was 172.9 months (range 18–476). The mean duration of biological treatment was 47.4 months (range 6-132). 32 patients have HAQ>1 and the fat biopsy were performed at 16 of them. We found statistically significant differences between the 2 groups (with or without amyloidosis) and they were recorded between CRP value, VASpatient (p<0.02) and ESR value (p<0.04). We didn’t find any significant difference between treatment duration, number of DMARDs, different anti-TNFα agents, swollen joints, DAS 28, sex, other comorbidities. Conclusions Amyloidosis is an entity that can influence the quality of life of patients with rheumatoid arthritis. We didn’t found any significant correlation with type of biological treatment. Further studies will be necessary to complete this results Disclosure of Interest None Declared